美国现役军人女性妊娠期日本脑炎疫苗接种的安全性研究
本研究基于美国国防部出生与婴儿健康研究项目2003-2014年192,570例现役军人女性妊娠数据,其中513例在妊娠期暴露于日本脑炎疫苗(474例在孕早期)。分析未发现疫苗接种与不良妊娠及婴儿健康结局的总体关联,仅在亚组分析中首次接种与低出生体重风险升高相关(RR=1.87,95%CI:1.12-3.13),总体结果为妊娠期日本脑炎疫苗安全性提供了 reassuring 证据。
要点
- 妊娠期日本脑炎疫苗暴露总体未增加不良妊娠及婴儿健康结局风险。
- 妊娠期接种>1剂疫苗时风险估计值升高(1.53-1.70),但95%CI宽且包含无效值。
- 亚组分析中首次接种与低出生体重风险升高相关(RR=1.87,95%CI:1.12-3.13),主分析未观察到。
核心结论
- 总体结果支持妊娠期日本脑炎疫苗接种的安全性,未发现与不良妊娠及婴儿健康结局的显著关联。
- 妊娠期接种多剂疫苗的风险估计值升高但无统计学意义,可能受妊娠未察觉影响。
- 低出生体重关联仅见于亚组分析中首次接种者,主分析未重现。
研究设计与样本
- 研究人群为2003-2014年美国国防部出生与婴儿健康研究项目中192,570例现役军人女性妊娠。
- 其中513例在妊娠期暴露于日本脑炎疫苗,474例暴露发生在孕早期。
- 采用多变量模型计算调整后风险估计值及95%置信区间,比较暴露与未暴露妊娠的妊娠及婴儿健康结局。
主要发现
- 妊娠期接种>1剂日本脑炎疫苗时,所有结局的风险估计值范围为1.53至1.70,但95%CI宽且包含无效值。
- 排除妊娠期暴露于其他非 routinely 推荐疫苗的妊娠后,妊娠期首次接种日本脑炎疫苗与低出生体重风险升高相关(RR=1.87,95%CI:1.12-3.13)。
- 主分析及亚组分析中所有其他关联均为无效。
临床怎么用
- 为处于日本脑炎流行区的现役军人女性妊娠期接种日本脑炎疫苗的安全性提供了总体令人安心的证据。
- 妊娠期首次接种日本脑炎疫苗与低出生体重的关联需在更大样本中进一步验证,临床决策时应结合个体风险评估。
局限性
- 妊娠期日本脑炎疫苗暴露例数较少(513例),尤其多剂接种者,导致风险估计值置信区间宽。
- 低出生体重关联仅见于亚组分析,可能受妊娠未察觉及混杂因素影响,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Japanese encephalitis (JE) vaccine is an inactivated vaccine that has shown no risks in pregnancy in animal models, but epidemiologic studies are lacking. U.S. military service members located in JE endemic regions are required to be vaccinated; understanding the potential adverse events (AEs), including AEs that may occur in pregnancy, is needed. Here, we assessed pregnancy and infant health outcomes in association with JE vaccination in pregnancy. METHODS: The study population consisted of 192,570 pregnancies to active duty women (2003-2014), captured in the Department of Defense Birth and Infant Health Research program. JE vaccine in pregnancy, vaccine count, formulation, trimester, and whether first career dose coincided with pregnancy were compared with unexposed pregnancies to assess risk of pregnancy and infant health outcomes. Adjusted risk estimates and 95% confidence intervals (CIs) were calculated by multivariable models. RESULTS: Of the 192,570 identifed pregnancies, 513 were exposed to the JE vaccine; 474 exposures occurred in the first trimester. For all outcomes, elevated risk estimates ranging from 1.53 to 1.70, were observed with receipt of >1 JE vaccine in pregnancy, though 95% CIs were wide and encompassed the null. First dose of JE vaccination in pregnancy was associated with a 1.87 (95% CI: 1.12-3.13) times increased risk of low birthweight (LBW) when excluding pregnancies exposed to other non-routinely recommended vaccinations in pregnancy. All other associations were null in both main and subset analyses. CONCLUSIONS: The overall results of these analyses provide reassuring findings for the safety of JE vaccination in pregnancy. Higher counts of JE vaccine received in pregnancy yielded large yet non-statistically significant risk estimates for all outcomes, though likely driven by lack of pregnancy awareness. An association was observed with LBW in subset analyses, but it was limited to women receiving their first JE vaccine and not observed in the larger main analyses.
引用
- Khodr ZG, Hall C, Chang RN, et al. Japanese encephalitis vaccination in pregnancy among U.S. active duty military women. Vaccine. 2020. PMID: 32423771. doi:10.1016/j.vaccine.2020.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。